Amgen ' s Bone Drug Disappointment Shows Limits Of Genetics In Drug Discovery
Romosozumab for osteoporosis was supposed to be an example of how genetic research can lead to better drugs. Instead, it may increase patients risk of heart attacks -- and may never make it to market.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NASDAQ:AMGN NYSE:SNY NASDAQ:REGN NYSE:MRK Source Type: news